0102 GMT - Sonic Healthcare gets a new bull at Bell Potter, where analyst Martyn Jacobs sees the pathology operator getting over what he calls its Covid-19 hangover. Jacobs initiates coverage of the stock with a buy rating, telling clients in a note that he expects Ebitda margins to start recovering from a rocky spell in FY 2025. Margins will expand by about 110 bps through fiscal FY he reckons. He says that growth is being driven by cost reductions, recent acquisitions, and a normalization of organic operations following Covid-driven disruption. Bell Potter puts a A$33.70 target price on the stock, which is up 1.0% at A$26.49. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
June 18, 2025 21:02 ET (01:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。